Australians progressing the work of a Nobel prize-winning chemist have developed a superbug-­destroying protein using ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

A new report from congressional researchers examines the state of law around a federal statute that prohibits gun possession ...

Wave Life Sciences Ltd. shows promise with AATD, DMD, and Huntington's programs. Click for my updated look at WVE stock and ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Citizen’s Petition Filed Requesting FDA Approve NurOwn™ On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug ...

Milestone Pharmaceuticals Inc. is a strong buy under $2 with FDA approval for Cardamyst expected in 2026, offering unique ...

Shares of Cogent Biosciences were higher after the company disclosed what it called positive top-line results from a recent trial of its treatment for certain types of mastocytosis, a rare disorder in ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Joseph Jacob, MD, discusses the promising impact of TAR-200.

Shares of Instil Bio jumped after federal regulators cleared the investigational new drug application for its tumor treatment AXN-2510. The stock was up 11% at $24.38 in early trading. Shares were ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.